Research progress on protein translational reprogramming in tumors

doi:10.16352/j.issn.1001-6325.2024.12.1736

Abstract

Abstract: Protein translational reprogramming is an important compensatory change made by cells in response to a variety of stimuli, resulting in rapid, specific changes to the cellular proteome. In tumor cells, this reprogramming is regulated through several mechanisms, including the internal ribosome entry site (IRES), cap-independent translational enhancers (CITE), and N6-methyladenosine (m6A) modifications. These processes play pivotal roles in controlling protein translational reprogramming, which is essential for tumorigenesis, progression, and treatment resistance. Further research into the function of protein translational reprogramming in tumors may reveal novel therapeutic targets and offer new avenues for cancer treatment.

Key words: protein translation, translational reprogramming, epithelial-mesenchymal transition, tumor drug resistance

CLC Number:

R730.2

FAN Ying, LIU Yang, LIU Yanyong. Research progress on protein translational reprogramming in tumors[J]. Basic & Clinical Medicine, 2024, 44(12): 1736-1740.

References

[1]Jia X, He X, Huang C, et al. Protein translation: biological processes and therapeutic strategies for human diseases[J]. Signal Transduct Target Ther, 2024, 9: 44. doi: 10.1038/s41392-024-01749-9.
[2]Gao X, Jin Y, Zhu W, et al. Regulation of eukaryotic translation initiation factor 4E as a potential anticancer strategy[J]. J Med Chem, 2023, 66: 12678-12696.
[3]Panwar V, Singh A, Bhatt M, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease[J]. Signal Transduct Target Ther, 2023, 8: 375. doi: 10.1038/s41392-023-01608-z.
[4]Zhao Y, Li C, Zhang Y, et al. CircTMTC1 contributes to nasopharyngeal carcinoma progression through targeting miR-495-MET-eIF4G1 translational regulation axis[J]. Cell Death Dis, 2022, 13: 250. doi: 10.1038/s41419-022-04686-z.
[5]Zhu Y, Xiao B, Liu M, et al. N6-methyladenosine-modified oncofetal lncRNA MIR4435-2HG contributed to stemness features of hepatocellular carcinoma cells by regulating rRNA 2'-O methylation[J]. Cell Mol Biol Lett, 2023, 28: 89. doi: 10.1186/s11658-023-00493-2.
[6]Yeh DW, Zhao X, Siddique HR, et al. MSI2 promotes translation of multiple IRES-containing oncogenes and virus to induce self-renewal of tumor initiating stem-like cells[J]. Cell Death Discov, 2023, 9: 141. doi: 10.1038/s41420-023-01427-9.
[7]Kampen KR, Sulima SO, Verbelen B, et al. The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL[J]. Leukemia, 2019, 33: 319-332.
[8]Ryan CS, Schröder M. The human DEAD-box helicase DDX3X as a regulator of mRNA translation[J]. Front Cell Dev Biol, 2022, 10: 1033684. doi: 10.3389/fcell.2022.1033684.
[9]Benboubker V, Boivin F, Dalle S, et al. Cancer cell phenotype plasticity as a driver of immune escape in melano-ma[J]. Front Immunol, 2022, 13: 873116. doi: 10.3389/fimmu.2022.873116.
[10]Dinh NTM, Nguyen TM, Park MK, et al. Y-Box binding protein 1: unraveling the multifaceted role in cancer development and therapeutic potential[J]. Int J Mol Sci, 2024, 25:717. doi: 10.3390/ijms25020717.
[11]Kovalski JR, Kuzuoglu-Ozturk D, Ruggero D. Protein synthesis control in cancer: selectivity and therapeutic targeting[J]. EMBO J, 2022, 41: e109823. doi: 10.15252/embj.2021109823.
[12]Zhang H, Zhou J, Li J, et al. N6-methyladenosine promotes translation of VEGFA to accelerate angiogenesis in lung cancer[J]. Cancer Res, 2023, 83: 2208-2225.
[13]Robichaud N, Hsu BE, Istomine R, et al. Translational control in the tumor microenvironment promotes lung metastasis: phosphorylation of eIF4E in neutrophils[J]. Proc Natl Acad Sci USA, 2018, 115: e2202-e2209.
[14]Wu C, Wang S, Cao T, et al. Newly discovered mechanisms that mediate tumorigenesis and tumour progression: circRNA-encoded proteins[J]. J Cell Mol Med, 2023, 27: 1609-1620.
[15]Fabbri L, Chakraborty A, Robert C, et al. The plasticity of mRNA translation during cancer progression and therapy resistance[J]. Nat Rev Cancer, 2021, 21: 558-577.
[16]Xue C, Gu X, Li G, et al. Expression and functional roles of eukaryotic initiation factor 4A family proteins in human cancers[J]. Front Cell Dev Biol, 2021, 9: 711965. doi: 10.3389/fcell.2021.711965.
[17]Zindy P, Bergé Y, Allal B, et al. Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors[J]. Cancer Res, 2011, 71: 4068-4073.
[18]Biswas B, Guemiri R, Cadix M, et al. Differential effects on the translation of immune-related alternatively polyadenylated mRNAs in melanoma and T cells by eIF4A inhibition[J]. Cancers, 2022, 14:1177. doi: 10.3390/cancers14051177.
[19]Marafie SK, Al-Mulla F, Abubaker J. mTOR: its critical role in metabolic diseases, cancer, and the aging process[J]. Int J Mol Sci, 2024, 25. doi: 10.3390/ijms25116141.
[20]Coleman N, Stephen B, Fu S, et al. Phase Ⅰ study of sapanisertib (CB-228/TAK-228/MLN0128) in combin-ation with ziv-aflibercept in patients with advanced solid tumors[J]. Cancer Med, 2024, 13: e6877. doi: 10.1002/cam4.6877.
[21]Chen X, An Y, Tan M, et al. Biological functions and research progress of eIF4E[J]. Front Oncol, 2023, 13: 1076855. doi: 10.3389/fonc.2023.1076855.
[22]Duffy AG, Makarova-Rusher OV, Ulahannan SV, et al. Modulation of tumor eIF4E by antisense inhibition: a phase Ⅰ/Ⅱ translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer[J]. Int J Cancer, 2016, 139: 1648-1657.
[23]Fang C, Xie H, Zhao J, et al. eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma[J]. Anticancer Drug, 2021, 32: 822-828.
[24]Nishida Y, Zhao R, Heese LE, et al. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML[J]. Leukemia, 2021, 35: 2469-2481.
[25]Kayastha F, Herrington NB, Kapadia B, et al. Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma[J]. Mol Med, 2022, 28: 101. doi: 10.1186/s10020-022-00534-0.